Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViroPharma Could Manufacture Cinryze "At Risk" Starting Next Year

This article was originally published in The Pink Sheet Daily

Executive Summary

Delay in application for industrial scale production illustrates the challenges that biosimilar manufacturers will face.

You may also be interested in...



Biosimilars: FDA's Meeting Notice Upgrades Safety To "Paramount"

Updated outline of November meeting discussion points includes several tweaks to the pharmacovigilance section.

Dyax Kalbitor Is Third To Market For HAE, But First For All Acute Attacks

Overcoming an FDA advisory committee that expressed doubts about efficacy and potential hypersensitivity reactions and a "complete response" letter asking for a Risk Evaluation and Mitigation Strategy, Dyax won approval for Kalbitor (ecallantide) Nov. 27 to treat acute attacks of hereditary angioedema in patients 16 and older

FDA Won’t Require A Verification Study For Genzyme’s Lumizyme

Genzyme expects to resubmit its BLA, which received a complete response, by mid-May and have a six-month review.

Related Content

Topics

UsernamePublicRestriction

Register

PS071348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel